Literature DB >> 2396195

Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers.

S C Atri1, J Misra, D Bisht, K Misra.   

Abstract

We used homologous platelet-derived wound healing factors (HPDWHF) to achieve complete healing of recalcitrant ulcers of diverse cause. Twenty-three patients with 27 skin ulcers who had been receiving conventional wound care with no evidence of healing for an average period of 25 weeks (range, 12 to 156 weeks) were studied. The patients were first subjected to controlled wound care for 3 months, with saline solution and silver sulfadiazine dressings used in all cases. At the end of this period, persistent nonhealing ulcers were treated by topical use of HPDWHF and silver sulfadiazine. Ulcer parameters were recorded on the first day and every week during therapy until complete epithelization was achieved in either group. Each ulcer acted as its own control. In the controlled wound care group, only three ulcers in three patients achieved complete healing; the remaining 24 ulcers in 20 patients failed to achieve even 50% healing in the stipulated 3-month period. However, when subjected to HPDWHF applications, these ulcers healed completely, 100% healing occurring in 9.67 +/- 4.9 weeks (range, 3 to 19 weeks), which is highly significant (p less than 0.01). The healing response to HPDWHF applications was of uniform progression over the weeks. Only the basic cause of the ulcer determined the healing rates in this group. The shortest and the longest time to achieve 100% healing occurred in patients with diabetes (6.88 +/- 2.97 weeks) and in the venous stasis group (14.00 +/- 7.07 weeks). Age, sex, location of ulcer, ulcer duration, and ulcer measurements had no influence on the HPDWHF-stimulated healing rates. This is the earliest report of HPDWHF-stimulated repair in chronic nonhealing skin ulcers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2396195

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Allogenic platelet gel in the treatment of pressure sores: a pilot study.

Authors:  Silvia Scevola; Giovanni Nicoletti; Federica Brenta; Paola Isernia; Marcello Maestri; Angela Faga
Journal:  Int Wound J       Date:  2010-04-23       Impact factor: 3.315

Review 2.  Healing the diabetic wound and keeping it healed: modalities for the early 21st century.

Authors:  Matthew J Claxton; David G Armstrong; Andrew J M Boulton
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

3.  Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response.

Authors:  M C Robson; D P Hill; P D Smith; X Wang; K Meyer-Siegler; F Ko; J S VandeBerg; W G Payne; D Ochs; L E Robson
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

Review 4.  Platelets as delivery systems for disease treatments.

Authors:  Qizhen Shi; Robert R Montgomery
Journal:  Adv Drug Deliv Rev       Date:  2010-07-07       Impact factor: 15.470

Review 5.  Autologous platelet-rich plasma for treating chronic wounds.

Authors:  Maria José Martinez-Zapata; Arturo J Martí-Carvajal; Ivan Solà; José Angel Expósito; Ignasi Bolíbar; Luciano Rodríguez; Joan Garcia; Carlos Zaror
Journal:  Cochrane Database Syst Rev       Date:  2016-05-25

6.  Favorable vocal fold wound healing induced by platelet-rich plasma injection.

Authors:  Seung Hoon Woo; Han-Sin Jeong; Jin Pyeong Kim; Eun-Ha Koh; Seon Uk Lee; Sung Min Jin; Dong Hoon Kim; Jin Hee Sohn; Sang Hyuk Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-02-05       Impact factor: 3.372

7.  Treatment of life-threatening wounds with a combination of allogenic platelet-rich plasma, fibrin glue and collagen matrix, and a literature review.

Authors:  Mehdi Asadi; Daryoush Hamidi Alamdari; Hamid Reza Rahimi; Mohsen Aliakbarian; Ali Jangjoo; Abbas Abdollahi; Mostafa Mehrabi Bahar; Ali Azadmand; Naser Forghani; Mohammad Nori Sadegh; Mohammad Esmail Khayamy; Alexander Seifalian
Journal:  Exp Ther Med       Date:  2014-05-29       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.